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Accepted 8 May 2015; Published online 16 May 2015AbstractObjectives: Our aim was to improve meta-analysis methods for summarizing a prediction model’s performance when individual partic-
ipant data are available from multiple studies for external validation.
Study Design and Setting: We suggest multivariate meta-analysis for jointly synthesizing calibration and discrimination performance,
while accounting for their correlation. The approach estimates a prediction model’s average performance, the heterogeneity in performance
across populations, and the probability of ‘‘good’’ performance in new populations. This allows different implementation strategies (e.g.,
recalibration) to be compared. Application is made to a diagnostic model for deep vein thrombosis (DVT) and a prognostic model for breast
cancer mortality.
Results: In both examples, multivariate meta-analysis reveals that calibration performance is excellent on average but highly hetero-
geneous across populations unless the model’s intercept (baseline hazard) is recalibrated. For the cancer model, the probability of ‘‘good’’
performance (defined by C statistic 0.7 and calibration slope between 0.9 and 1.1) in a new population was 0.67 with recalibration but
0.22 without recalibration. For the DVT model, even with recalibration, there was only a 0.03 probability of ‘‘good’’ performance.
Conclusion: Multivariate meta-analysis can be used to externally validate a prediction model’s calibration and discrimination perfor-
mance across multiple populations and to evaluate different implementation strategies. Crown Copyright  2016 Published by Elsevier
Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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A crucial part of medical research is to develop risk
prediction models. These aim to accurately predict disease
and outcome risk in individuals [1e3], thereby informing
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by/4.0/).individuals with a high predicted risk of future disease
(e.g., cardiovascular events) may be advised to modify their
lifestyle and behavior choices (e.g., smoking, exercise), and
diseased individuals may be grouped (e.g., stage of cancer)
according to future outcome risk so that clinical decisions
(such as treatment options, monitoring strategies) can be
tailored accordingly. Two well-known examples are QRISK
[4] and the Nottingham Prognostic Index [5]. They are typi-
cally implemented within a multivariable regression frame-
work, such as logistic or Cox regression, which provides an
equation to estimate an individual’s risk based on values of
multiple predictors (prognostic factors [6]) such as age, bio-
markers, and genetic information.
A key stage of prediction model research is model devel-
opment [2]. This identifies important predictors andcess article under the CC BY license (http://creativecommons.org/licenses/
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Key findings
 Given individual participant data (IPD) from mul-
tiple external validation studies, meta-analysis
enables researchers to summarize prediction model
performance, in terms of both average performance
and consistency in performance across popula-
tions. It thereby allows different implementation
strategies (e.g., recalibration) to be formally
compared.
 A multivariate meta-analysis approach should be
used to jointly evaluate discrimination and calibra-
tion performance, while accounting for their cor-
relation. This can be used within internaleexternal
cross-validation (to also incorporate a model devel-
opment phase) or when IPD from multiple studies
are available for external validation of existing
models.
What this adds to what was known?
 Before implementation, risk prediction models
require validation in data external to that used for
model development. This is best achieved using
IPD from multiple studies, so that model perfor-
mance can be examined and quantified across mul-
tiple populations of interest. A good prediction
model will have satisfactory performance on
average across all external validation data sets
and crucially little or no between-study heteroge-
neity in performance.
 Our examples show that a prediction model may
have excellent average performance but with het-
erogeneity (inconsistency) in performance across
populations. Recalibration of the model’s intercept
term (or baseline hazard) in the intended popula-
tion might reduce heterogeneity and thereby
improve the probability of acceptable model per-
formance when applied in new populations.
What is the implication and what should change
now?
 When IPD are available from multiple studies for
external validation of a prediction model, re-
searchers should use multivariate meta-analysis to
jointly summarize calibration and discrimination
performance and to identify how best to implement
the model in new populations.
develops the risk prediction equation using an available
data set; it usually also examines the model’s apparent
performance in this same data or uses internal validation
K.I.E. Snell et al. / Journal of Cltechniques (such as bootstrap resampling) to examine and
adjust for optimism in performance [7]. The next stage is
external validation [8e10]. This uses data external to the
model development data and its source and examines
whether the model predictions are accurate in another
(but related) situation. The aim was to ascertain the model’s
generalizability to the intended populations for use [11] and
to identify the best implementation strategy (e.g., recalibra-
tion of the intercept).
Unfortunately, most prediction research focuses on
model development, and there are relatively few external
validation studies [12]. However, nowadays, there is
increasing access to multiple data sets, as evident in
meta-analyses using individual participant data (IPD) from
multiple studies [13,14]. This provides an exciting opportu-
nity to perform external validation on multiple occasions
[15,16]. Model development and external validation can
even occur simultaneously, using an approach called inter-
naleexternal cross-validation [17,18]. This develops a
model in all but one of the IPD studies, and then, its
external validity is immediately checked in the omitted
study. This process is repeated across all rotations of the
omitted study, to measure external validity in each distinct
IPD study.
Given multiple external validation studies, meta-analysis
methods are needed to synthesize and summarize model
performance appropriately across the available populations.
Van Klaveren et al. [16], Pennells et al. [15], and, within
internaleexternal cross-validation, Royston et al. [17]
consider approaches to summarize validation performance
across multiple studies or clusters. These focus mainly on
producing pooled estimates of discrimination performance;
that is, a model’s ability to distinguish correctly between
patients with and without the outcome of interest.
Researchers should also be interested in summarizing cali-
bration performance, which is the agreement between a
model’s predicted risk and the observed risk. Calibration
is often ignored in external validation research [19],
although it is fundamental that observed and predicted risks
should closely agree. Moreover, baseline risk may vary
across study populations, and so, a model’s implementation
may need to be tailored to each population (often referred
to as recalibration) to improve calibration performance in
new populations.
In this article, we propose multivariate meta-analysis for
jointly synthesizing discrimination and calibration perfor-
mance, while accounting for their correlation. This can be
used within internaleexternal cross-validation (to also
incorporate a model development phase) or when IPD from
multiple studies are available for external validation of ex-
isting models. We show that the multivariate approach sum-
marizes a prediction model’s average discrimination and
calibration performance and quantifies the heterogeneity
in performance across populations. It also allows re-
searchers to predict the potential calibration and discrimi-
nation of a model when it is applied to a new population
42 K.I.E. Snell et al. / Journal of Clinical Epidemand can be used to estimate the probability of ‘‘good’’ per-
formance (as predefined by the user). Using two real exam-
ples, we illustrate how this enables researchers to compare
the performance of different implementation strategies
(e.g., recalibration of the intercept term) to help identify
the best strategy for applying the model in practice.
The article now proceeds by introducing the proposed
multivariate meta-analysis methodology for summarizing
and comparing validation performance (Section 2). Two
clinical examples are then used to illustrate the approach
(Section 3), one for diagnosis and one for prognosis, and
we conclude with some discussion (Section 4).2. Meta-analysis of predictive performance statistics
from multiple external validation studies
External validation of a prediction model requires eval-
uation of its predictive performance, in terms of both cali-
bration and discrimination. There are many statistical
measures available for this purpose [1,20]. Here, we focus
on those most commonly used: the C statistic [20,21], the D
statistic [22,23], the calibration slope [1,20], calibration-in-
the-large [1], and the expected/observed number of events.
These are defined in the Appendix at www.jclinepi.com.
We focus here on how to meta-analyze such performance
statistics when they are estimated in multiple external vali-
dation studies.2.1. Obtaining suitable data for meta-analysis
The meta-analysis approach requires an estimate of each
performance statistic of interest (e.g., C statistic, calibration
slope) from each external validation study. Given IPD,
these can be calculated in each validation study using
appropriate statistical methods, as described elsewhere
[1,20,23]. However, meta-analysis also requires the varian-
ceecovariance matrix of the performance statistics in each
study: in other words, the variance of each performance es-
timate and (for multivariate meta-analysis) the correlation
between all pairs of estimates. A general approach to obtain
these is via nonparametric bootstrapping, as described in
the Appendix at www.jclinepi.com.2.2. Univariate random-effects meta-analysis
For clarity, before proposing our multivariate approach,
we first describe a univariate random-effects meta-analysis
that is applicable separately to each performance measure
of interest [24,25]. In external validation study i, let Yij
be the estimate of the jth performance statistic of interest,
and let S2ij be its sample variance (derived from bootstrap-
ping and assumed known), then the univariate meta-
analysis can be written as:Yij | N

mij; S
2
ij

mij | N

mj;t
2
j
 ð1Þ
iology 69 (2016) 40e50Equation (1) assumes the Yij are normally distributed
about the ith study’s true validation performance, mij, and
that the mij are also normally distributed with an average
of mj and a between-study standard deviation of tj. There
are several frequentist methods that can be used for estima-
tion of a random-effects meta-analysis; here, we use
restricted maximum likelihood (REML) [26]. With the
addition of prior distributions for unknown parameters, a
Bayesian approach is also possible, for example, using
Gibbs sampling. An approximate 100(1-a)% confidence in-
terval (CI) for the average performance, mj, is obtained bybmj 61:96 SEðbmjÞ, where SEðbmjÞ is the standard error of bmj:
White [27] proposed that SEðbmjÞ is inflated to account for
the uncertainty in the estimated tj, and we implement this
here.
2.3. Summarizing consistency in model performance
On its own, bmj is an incomplete summary because it
does not adequately summarize the consistency in perfor-
mance across studies. Estimates such as I2 (the percentage
of the total variation in study estimates that is due to
between-study heterogeneity [28]) and bt2j are thus also
helpful [29]. However, when evaluating performance statis-
tics of a risk prediction model, we are examining its gener-
alizability, in other words, its robustness when applied in
new populations that differ from those it was developed
in [11]. Thus, consistency is best expressed by a
100(1a)% prediction interval for the performance of the
model in a new population [24,25]. This is derived bybm j6 tf; N2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃbt2j þVbmj
q
ð2Þwhere tf; N2 is the 100ð1f=2 Þ% percentile of the t-
distribution for N  2 degrees of freedom (N 5 no. of
studies), VðbmjÞ 5 SEðbmjÞ2, and f is typically taken to
be 0.05 to give a 95% interval. The use of a t-distribution,
rather than a normal distribution, is used to account for
the uncertainty in bt2j [24]. The prediction interval thus in-
dicates the performance expected in a new (external
validation) study, similar to those included in the meta-
analysis.2.4. Multivariate meta-analysis
Our multivariate approach is an extension of Equation
(1) [30] and allows the joint synthesis of all predictive per-
formance measures of interest from the i 5 1 to N external
validation studies, while accounting for their within- and
between-study correlation. Let there be j 5 1 to J measures
of interest and let Yi be a vector containing the available J
estimates ðYi1; Yi2;.; YiJÞ of the measures in the ith
43K.I.E. Snell et al. / Journal of Clinical Epidemiology 69 (2016) 40e50validation study. The general multivariate meta-analysis
model is as follows:Yi jqi |MVN qi;Sið Þ
qi |MVN m;Sð Þ ð3ÞHere, MVN denotes a multivariate normal distribution,
qi contains the true underlying effects for the J perfor-
mance measures for the ith study, Si is the within-study var-
ianceecovariance matrix for the ith study (assumed known)
containing the J variances of the estimates (in the diagonal:
S2i1; S
2
i2;.; S
2
iJ) and their covariances (in the off diagonal;
e.g., rWið1;2ÞSi1Si2 is the within-study covariance for mea-
sures 1 and 2, where rWið1;2Þ is their within-study correla-
tion caused by estimates derived from the same patients),
m contains the J means for the measures of interest, and
S is the between-study varianceecovariance matrix con-
taining the J between-study variances (in the diago-
nalt21; t
2
2;.; t
2
J) and their between-study covariances (in
the off diagonal; e.g., the between-study covariance for
measures 1 and 2 is rBð1;2Þt1t2, where rBð1;2Þ is their
between-study correlation induced by differences in study
populations and settings). The number of rows in each vec-
tor is equal to the number of measures. In its simplest form
with two measures of interest (e.g., C statistic and calibra-
tion slope), Equation (3) can be expressed as a bivariate
meta-analysis (Appendix at www.jclinepi.com).
REML can again be used for estimation, although other
options are available [30,31]. Multivariate extensions to I2
can also be calculated [26,31], giving the fraction of the to-
tal variability due to between-study variability for each per-
formance statistic (I2J ).
2.5. Making joint inferences across multiple
performance measures
After Equation (3) is estimated, marginal confidence and
prediction intervals for each performance measure can be
obtained using the formulae given in the univariate section.
However, by accounting for their correlation, the multivar-
iate approach also enables joint inferences. For instance,
extending Equation (2) to a bivariate t-distribution with k
e 2 degrees of freedom, one can obtain a joint 95% predic-
tion region for two performance measures of interest (e.g.,
the C statistic and the calibration slope) in a new popula-
tion. Joint probabilistic inferences can also be made if we
assume the multivariate t-distribution is an approximate
posterior distribution (i.e., we assume it is obtained from
a Bayesian analysis with uninformative priors and give it
means, variances, and covariances obtained from REML
estimation of Equation (3)dsee Supplementary Material
1/Appendix B at www.jclinepi.com for full details [32]).
For example, one can derive the joint probability that the
C statistic will be above 0.7 and the calibration slope will
be between 0.9 and 1.1 in a new population. A fully
Bayesian approach can also be used to derive such posterior
inferences by formally specifying prior distributions andcombining them with the likelihood, then using, for
example, Gibbs sampling to take samples from the exact
posterior distributions. Riley et al. [33] describe the
Bayesian approach to multivariate meta-analysis with IPD.
2.6. Comparing the predictive performance of different
implementation strategies
When applying a prediction model to a new population,
different implementation strategies might be used regarding
the choice of model intercept (baseline hazard). This is
illustrated in Section 3.1 and Section 3.2, and, for example,
includes recalibration. Meta-analysis of performance statis-
tics allows such implementation strategies to be formally
compared. The aim is to identify an implementation strat-
egy that, for each performance measure, has excellent per-
formance on average (indicated by bmj); small values of
between-study heterogeneity (indicated by btj and/or I2J );
and a narrow prediction interval that suggests consistently
good performance in new populations. Multivariate meta-
analysis even allows the competing strategies to be ranked
according to their overall performance: for example,
according to the joint probability that, in a new population,
the C statistic will be above 0.7 and the calibration slope
will be between 0.9 and 1.1. The strategy with the largest
probability will be ranked first.
2.7. Meta-regression and examining covariates
Meta-analysis Equation (3) can be extended to a multi-
variate meta-regression that includes study-level covariates
to explain between-study heterogeneity, such as treatment
policies, population characteristics (e.g., mean age), year
of investigation, and length of follow-up. Competing imple-
mentation strategies can then be evaluated and compared
for specific subgroups of studies (e.g. those done within
the last few years, those with consistent treatment policies,
and those with the same case-mix, and so forth). This may
help to identify populations where model performance is
satisfactory and others where it is inadequate, to inform
the model’s generalizability and applicability [11]. A nice
example of a meta-regression to examine the impact of
case-mix variation on model performance is given by
Pennells et al. [15], who identify that studies with a higher
standard deviation of age are strongly associated with a
higher C statistic and D statistic. Model performance can
also be examined for patient-level covariates; for example,
discrimination and calibration could be estimated for males
and females separately. Equation (3) can then be applied to
summarize each subgroup or even the difference between
subgroups.
3. Applied examples
We now illustrate the proposed meta-analysis methods
with two applied prediction model examples, one for diag-
nosis and one for prognosis, and compare the performance
44 K.I.E. Snell et al. / Journal of Clinical Epidemiology 69 (2016) 40e50of different implementation strategies, including
recalibration.
3.1. Diagnostic example: prediction of existing deep
vein thrombosis (DVT)
3.1.1. Data, model development, and competing
implementation strategies
We used IPD from 12 studies to develop a diagnostic
prediction model for the risk of having DVT in patients
who were suspected of having DVT, as described previ-
ously [34]. A total of 10,002 patients were available across
the 12 studies (with study sample sizes ranging from 153 to
1,768 patients), and 1,864 (19%) patients truly had DVT.
This IPD is used here only for illustration purposes and
not to develop or recommend the optimal diagnostic model
to be used in medical practice.
The prediction model was developed using logistic
regression, including a separate intercept for each study
and three predictors chosen a priori: sex (male 5 1,
female 5 0), surgery (recent surgery or bedridden 5 1,
no recent surgery or bedridden 5 0), and calf difference
(3 cm 5 1,!3 cm 5 0). However, three different imple-
mentation strategies were considered (for the model inter-
cept) when applying the developed model to the external
validation data set:
Strategy (1): Use a new intercept estimated in the
external validation data set itself. This is a form of model
recalibration [35].
Strategy (2): Use the estimated weighted average of the
study intercept terms from the developed model.
Strategy (3): Use the estimated intercept for one of the
studies in the developed model that had the most similar
prevalence of DVT to the external validation study.
Internaleexternal cross-validation was undertaken for
each implementation strategy, and their predictive perfor-
mance then summarized and compared across the 12
external validation studies using our multivariate meta-
analysis approach.
3.1.2. Results
Regardless of which study was excluded, the predictor
effect estimates (log odds ratios) were very similar in each
cycle of the internaleexternal cross-validation approach
[Supplementary Material 2/Appendix B at www.jclinepi.
com shows the parameter estimates in each cycle, and the
intercept to be implemented in strategy (3)]. During
external validation of the model, for each implementation
strategy, four validation statistics were estimated:
calibration-in-the-large, calibration slope, the C statistic,
and the ratio of expected and observed DVT cases, as
defined in the Appendix at www.jclinepi.com. These results
are shown (with standard errors) in Supplementary Material
3(A)/Appendix B at www.jclinepi.com for each of the stra-
tegies. Their within-study correlations, obtained from boot-
strapping with 1,000 samples, are shown in SupplementaryMaterial 3(B)/Appendix B at www.jclinepi.com. These are
large (between þ0.90 and þ0.98) for the calibration slope
and C statistic, indicating a strong positive relationship
between them. In other words, as the observed calibration
slope of model predictions decreases (becomes flatter),
the observed discrimination of the model predictions also
decreases (less separation); conversely, when model predic-
tions produce a steeper observed calibration slope, the
discrimination is improved. The other measures of calibra-
tion (calibration-in-the-large and expected/observed) mea-
sure overall agreement and thus are not affected so much
by changes in discrimination; thus, their within-study corre-
lation with the C statistic is close to zero. There is a perfect
negative correlation between log(expected/observed) and
calibration-in-the-large by definition.
The multivariate meta-analysis results for each statistic
are shown in Table 1. The meta-analysis results for the C
statistic are practically the same in all implementation stra-
tegies, as are those for the calibration slope. The mean C
statistic is 0.69 (95% CI: 0.67, 0.71), indicating moderate
discrimination. There is a small amount of between-study
heterogeneity (btz0.02; I2 z 37%), leading to a 95% pre-
diction interval of 0.64e0.73, revealing fairly consistent
discrimination performance across studies (Fig. 1). The
mean calibration slope is around 0.98 (95% CI: 0.85,
1.10), which is close to the ideal value of one although indi-
cating very slight overprediction. The amount of between-
study heterogeneity is large (btz0.16; I2 z 59%), leading
to a wide 95% prediction interval [e.g., 0.59e1.38 for strat-
egy (2)]. This contains values well above and well below
one, which, respectively, suggest that in some populations,
the predicted probabilities vary too little (i.e., the model is
underfitted and/or assigns probabilities that are too similar
across individuals) and in others they vary too much (i.e.,
the model is overfitted to the development sample and as-
signs probabilities that vary too much across individuals).
This illustrates how the average performance is an incom-
plete picture; calibration slope is good on average but could
be poor in particular populations (Fig. 2).
Calibration-in-the-large does differ more importantly
across implementation strategies (Table 1), as it is sensitive
to the choice of intercept. The meta-analysis results reveal
it is, on average, slightly worse for strategy (1) as there is a
small overprediction in the proportion with DVT (0.13;
95% CI: 0.19, 0.08). However, there is almost no het-
erogeneity in the calibration-in-the-large (bt50.008;
I2 5 1%), leading to a narrow 95% prediction interval
(0.20 to 0.07). Using strategy (2) or (3) the average
calibration-in-the-large is closer to zero(0.004 and
0.047, respectively) but comes at the expense of slightly
larger between-study heterogeneity (bt50.53 and 0.27,
I2 5 97% and 89%, respectively), leading to wider predic-
tion intervals. For example, for strategy (2), the 95% pre-
diction interval is 1.24 to 1.23.
Instead of calibration-in-the-large, it is perhaps easier to
interpret the expected/observed proportion of DVT cases
Table 1. Trivariate meta-analysis resultsa for the calibration and discrimination performance of the DVT model for each implementation strategy
Strategy Validation statistic Estimate (95% CI) of mean, m 95% Prediction interval I2 (%) bt (95% CI)
Strategy (1):
Develop using logistic regression and
implement with intercept estimated
in external validation study
Calibration-in-the-large 0.130 (0.185, 0.075) 0.195, 0.065 1 0.008
Calibration slope 0.975 (0.855, 1.097) 0.597, 1.353 57 0.158
Log(expected/observed) 0.086 (0.047, 0.124) 0.041, 0.128 0 0.0009
C statistic 0.687 (0.670, 0.704) 0.645, 0.729 34 0.017
Strategy (2):
Develop using logistic regression
and implement with average study
intercept taken from developed
model
Calibration-in-the-large 0.004 (0.313, 0.305) 1.240, 1.232 97 0.532
Calibration slope 0.980 (0.853, 1.107) 0.585, 1.375 59 0.165
Log(expected/observed) 0.022 (0.206, 0.250) 0.887, 0.931 97 0.391
C statistic 0.687 (0.669, 0.705) 0.640, 0.734 37 0.019
Strategy (3):
Develop using logistic regression and
implement with intercept taken from
a study used in development data
with a similar prevalence
Calibration-in-the-large 0.047 (0.120, 0.214) 0.584, 0.678 89 0.270
Calibration slope 0.976 (0.851, 1.102) 0.578, 1.375 59 0.167
Log(expected/observed) 0.029 (0.150, 0.093) 0.485, 0.427 89 0.195
C statistic 0.687 (0.669, 0.705) 0.640, 0.734 38 0.019
Abbreviations: DVT, deep vein thrombosis; CI, confidence interval.
a A trivariate meta-analysis was fitted to calibration-in-the-large, calibration slope, and C statistic and then again for log(expected/observed),
calibration slope, and C statistic. Perfect negative correlation between calibration-in-the-large and expected/observed within studies prevents all
four measures being analyzed together (due to collinearity). Results were practically the same for calibration slope and C statistic, regardless of the
trivariate model fitted.
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rowest prediction interval for strategy (1) and slightly
improved average performance for strategies (2) and (3).
The 95% prediction interval for expected/observed for strat-
egy (1) suggests the overall agreement is likely to be reason-
able in new populations (1.05e1.14), with the number of
DVTcases overpredicted by between 5%and 14%.However,
the 95% prediction interval is unsatisfactory for the other
strategies; for example, it is 0.41e2.54 for strategy (2) indi-
cating the number of predicted DVT cases in a new popula-
tion could range from 59% too few up to 154% too many.Fig. 1. Forest plot showing the C statistic results from the trivariate random
implemented using strategy (2).Overall, therefore, strategy (1) appears best as it removes
heterogeneity in the calibration-in-the-large and expected/
observed, and maintains similar discrimination across popu-
lations. However, the prediction model would benefit from
additional predictors, as current discrimination is only mod-
erate and there is large heterogeneity in calibration slope.
This is confirmed by a joint probability of only 0.03 that strat-
egy (1) will give a C statistic0.7 and a calibration slope be-
tween 0.9 and 1.1 in a new population (Table 2). If the criteria
for model discrimination is relaxed to a C statistic 0.65,
then the joint probability improves but only to 0.43.-effects meta-analysis result (Table 1) for the DVT prediction model
Fig. 2. Forest plot showing the calibration slope result from the trivariate random-effects meta-analysis (Table 1) for the DVT prediction model
implemented using strategy (2).
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breast cancer patients
3.2.1. Data, model development, and competing
implementation strategies
We used IPD from eight cohort studies (relating to eight
different countries from Look et al. [36]) to develop and
evaluate a prognostic prediction model for the risk of mor-
tality over time in women recently diagnosed with breast
cancer. In total, there were 7,435 patients (ranging from
69 patients to 3,242 per study) and 2,043 events. The
maximum follow-up duration was 120 months, and the
median follow-up duration across all studies was
86.3 months. Internaleexternal cross-validation was used,
and, in each cycle, a RoystoneParmar flexible parametric
survival model was fitted [37e39], with the baselineTable 2. Joint predicted probability of ‘‘good’’ discrimination and calibration
strategies, derived using the multivariate meta-analysis results for the C sta
Calibration
slope required
Minimum C
statistic required
Joint predicted
Strategy (1):
Develop using logistic
regression and implement
with intercept estimated in
external validation study
Devel
and im
intercep
0.9e1.1 0.70 0.027
0.8e1.2 0.70 0.146
0.9e1.1 0.65 0.427
0.8e1.2 0.65 0.728
Abbreviation: DVT, deep vein thrombosis.cumulative hazard function modeled using restricted cubic
splines (with four knots deemed sufficient) and predictor
effects (hazard ratios) assumed constant over time. A set
of eight candidate predictors was considered at each cycle:
age, tumor type, tumor grade, tumor size, number of posi-
tive nodes, menopausal status, adjuvant therapy, and hor-
mone receptor status. Backward selection was used, with
P O 0.05 taken for exclusion. Separate but proportional
baseline hazard functions were included for each country;
that is, one study was taken as the reference group, and
others were allowed a country-specific adjustment factor.
When applying the developed model to the external valida-
tion study, three different implementation strategies were
considered (in regard the baseline hazard):
Strategy (1): Use a new country-specific adjustment fac-
tor as estimated in the validation study itself. This is a formperformance of the DVT model for each of the three implementation
tistic and calibration slope shown in Table 1
probability of meeting criteria in new population
Strategy (2):
op using logistic regression
plement with average study
t taken from developed model
Strategy (3):
Develop using logistic regression and
implement with intercept taken from
a study used in development data with
a similar prevalence
0.037 0.037
0.158 0.156
0.413 0.409
0.712 0.707
47K.I.E. Snell et al. / Journal of Clinical Epidemiology 69 (2016) 40e50of recalibration but assumes the baseline hazard in the vali-
dation study and the development studies are proportional.
Strategy (2): Use a weighted average of the estimated
country-specific adjustment factors from the developed
model.
Strategy (3): Use the country-specific adjustment factor
for a country that was included in the developed model and
is closest geographically to the validation country.
Internaleexternal cross-validation was undertaken for
each strategy, and their predictive performance then sum-
marized and compared across the eight external validation
studies using meta-analysis.
3.2.2. Results
The predictor effect estimates (log hazard ratios) were
similar in each cycle of the internaleexternal cross-
validation approach (results available on request). The
backward selection retained all candidate predictors in each
cycle, apart from menopausal status that was always
excluded. For each implementation strategy, we evaluated
model performance in each external validation study by
estimating Harrell’s C statistic [20], the D statistic
[22,40], and the calibration slope between the predicted
hazard function and the observed hazard function, as
defined in the Appendix at www.jclinepi.com. The esti-
mates, with their variances and within-study correlation,
are shown in Supplementary Material 4/Appendix B at
www.jclinepi.com. Within-study correlations were all pos-
itive and generally moderate to large.
Multivariate meta-analysis of the validation statistics is
summarized in Table 3 for each implementation strategy.
The summary C statistic and D statistic results are barely
affected by the choice of strategy. The average C statistic
is 0.71, and its 95% prediction interval is 0.66e0.76,
suggesting consistently moderate discrimination across
populations. The average D statistic is about 0.33, whichTable 3. Trivariate random-effects meta-analysis results for calibration an
implementation strategy
Strategy Validation statistic
Pooled es
(95%
Strategy (1):
Develop using RoystoneParmar and
implement with baseline hazard
estimated in validation study
Calibration slope 1.003 (0.971
C statistic 0.711 (0.690
D statistic 0.328 (0.215
Strategy (2):
Develop using RoystoneParmar model
and implement with the estimated
average baseline hazard from
developed model
Calibration slope 0.994 (0.835
C statistic 0.711 (0.691
D statistic 0.332 (0.212
Strategy (3):
Develop using RoystoneParmar model
and implement with the estimated
baseline hazard from the closest
geographical country
Calibration slope 0.961 (0.741
C statistic 0.710 (0.687
D statistic 0.330 (0.211
Abbreviation: CI, confidence interval.
a Defined by a C statistic 0.7 and an calibration slope between 0.9 aequates to a moderate hazard ratio of 1.39 (95% CI: 1.23,
1.57) between two equal sized groups across the prognostic
index. However, D is inconsistent across populations (I2 is
about 87%), and thus, its prediction interval is wide
(Table 3).
Calibration slope is affected by the choice of strategy.
For strategy (1), which allows recalibration in the validation
study, the calibration slope is excellent. The meta-analysis
gives an average calibration slope of 1.003, with only
moderate heterogeneity (I2 5 35%) leading to a narrow
prediction interval of 0.93e1.08. In contrast, strategies
(2) and (3) perform poorly. Although average calibration
is excellent, there is large between-study heterogeneity
[e.g., I2 5 99% for strategy (3)] leading to wide predictions
intervals [e.g., 0.15e1.77 for strategy (3)]. This again
reveals how average performance is an incomplete and
potentially misleading summary of performance.
Fig. 3 shows joint prediction ellipses for the C statistic
and the calibration slope, derived using the multivariate
meta-analysis results for each strategy. For implementation
strategy (1), there is a joint probability of 0.67 for a C
statistic  0.7 and a calibration slope between 0.9 and
1.1; however, the probability is only 0.15 for strategy (3)
and 0.22 for strategy (2).
Strategy (1) thus performs best, but it requires recalibra-
tion of the model in new countries and may be difficult to
implement. We therefore sought to improve strategy (2),
which does not include recalibration, by identifying the cause
of heterogeneity in its calibration performance. It was
observed that study 3 gave the poorest calibration slope on
external validation of themodels, most likely due to the base-
line hazard in study 3 being different in shape (nonpropor-
tional) to those other studies. Extending Equation (3) to a
multivariate meta-regression with a covariate for country
(15 study 3, 05 otherwise) explained a large part of the het-
erogeneity (P! 0.001). We repeated the internaleexternald discrimination performance of the breast cancer model for each
timate
CI)
95% Prediction
interval
I squared
(%)
Estimate
of t
Joint probability of
‘‘good’’a performance
in a new population
, 1.036) 0.927, 1.080 35 0.026 0.67
, 0.733) 0.657, 0.766 49 0.019
, 0.442) 0.056, 0.713 87 0.146
, 1.153) 0.411, 1.577 98 0.224 0.22
, 0.732) 0.662, 0.761 43 0.017
, 0.452) 0.080, 0.745 88 0.157
, 1.181) 0.148, 1.775 99 0.313 0.15
, 0.734) 0.653, 0.767 50 0.020
, 0.450) 0.068, 0.728 87 0.151
nd 1.1.
Fig. 3. Summary of validation performance of the breast cancer model for each implementation strategy, with regard to the C statistic and the
calibration slope results from the trivariate meta-analysis (Table 3).
48 K.I.E. Snell et al. / Journal of Clinical Epidemiology 69 (2016) 40e50cross-validation approach for strategy (2) but omitted study 3
for the entire process. External validation performance was
improved, as heterogeneity in calibration slope was reduced
(bt 5 0.156 excluding study 3, bt 5 0.22 including study 3),
and thus, its 95% prediction interval was narrower
(Supplementary Material 5/Appendix B at www.jclinepi.
com). The joint probability for a C statistic 0.7 and a cali-
bration slope between 0.9 and 1.1 was improved to 0.32 but
still considerably worse than strategy (1), indicating recali-
bration remains preferable.4. Discussion
We have proposed a multivariate meta-analysis approach
for summarizing and comparing prediction model
performance across multiple external validation studies
using IPD. This can be used within internaleexternal
cross-validation to also incorporate a model development
phase or when IPD from multiple studies are available
for external validation of existing models. Each of the sta-
tistical methods involved (such as obtaining within-study
correlations and fitting the multivariate equation) only take
up to a few minutes to perform using computer software
such as Stata (Texas, USA) and provide results that improve
the interrogation of a prediction model’s performance and
its implementation strategy.
Currently, most external validation research is undertaken
using a single data set. However, multivariate meta-analysis
of IPD is a novel way to examine the overall performance and
generalizability of a prediction model across multiple data
sets [13,15,16]. A good model will have satisfactory perfor-
mance on average across all external validation data sets. But
ideally, there should also be little or no between-study hetero-
geneity in performance. Our examples showed that a predic-
tion model may have excellent average performance but may
not have consistent performance across data sets. Such het-
erogeneity is rarely considered in external validationresearch but should be routinely examined where possible,
in particular to identify the best implementation strategy. In
our examples, the investigation of heterogeneity revealed
that recalibration of the intercept term to the validation pop-
ulation was essential; otherwise, there was considerable
inconsistency in calibration performance of our prediction
models. The importance of intercept recalibration is also
shown elsewhere [41,42]. However, it may not entirely re-
move the issue ofmiscalibration, as seen in theDVTexample
where there remained slight overprediction even after recali-
bration. In particular, if there is also heterogeneity in predic-
tor effects, then one may also need to recalibrate these to the
intended population; however, this defeats the purpose of the
initial research (i.e., to develop a predictionmodel that can be
used widely and easily) and rather indicates that additional
and/or more homogenous predictors are required.
Heterogeneity in discrimination performance was also
observed in our examples. This may also be due to heteroge-
neity in predictor effects across populations and/or different
case-mix distributions across populations, as populations
with wider ranges of continuous predictors often have better
discrimination [15]. For such reasons, incorporating
matched caseecontrol studies alongside cohort studies
may increase heterogeneity in discrimination performance,
as the former typically have narrower ranges of predictors
[43]. Another potential cause of heterogeneity in perfor-
mance of a prognostic prediction model is follow-up time,
and also, heavy censoring may bias Harrell’s C statistic,
prompting G€onen and Heller [44] to propose an alternative.
Such factors may also impact the magnitude of between-
study correlation in the performance measures.
As external validation of a prediction model usually
requires multiple statistical measures of performance, in
particular at least one for calibration and one for discrimi-
nation [8,19], our multivariate meta-analysis approach
jointly synthesizes all measures together across multiple
validation studies. This accounts for their within-study
and between-study correlation [45], which may arise
49K.I.E. Snell et al. / Journal of Clinical Epidemiology 69 (2016) 40e50because measures are highly related [33]. For example, the
C statistic and D statistic typically have moderate to large
positive within-study correlation [as seen in
Supplementary Material 4(B)/Appendix B at www.
jclinepi.com] as they are both measures of discrimination
and within studies are estimated on the same patients. Simi-
larly, the calibration slope and C statistic may also be corre-
lated between studies, for instance, if the between-study
heterogeneity in predictor effects causes calibration slope
to become greater than 1 as discrimination improves but
less than 1 as discrimination worsens. Accounting for such
correlation in the meta-analysis allows the borrowing of
strength across performance measures to potentially reduce
bias and improve precision [46,47]. Furthermore, it is
crucial to account for correlation when computing joint
probabilities of model performance, such as the magnitude
of the C statistic and calibration slope, as otherwise infer-
ences may be misleading [45].
Our intention was to illustrate how the multivariate
meta-analysis approach allows researchers to summarize
both discrimination and calibration. We focused on well-
known statistical criteria, such as the calibration slope,
(Harrell’s) C statistic, and Royston and Sauerbrei’s D
statistic. However, we recognize that the criteria for a
‘‘good’’ prediction model is open to much debate [48],
and readers may prefer to meta-analyze other statistical
measures available, including alternatives to Harrell’s C
statistic [44]. Clinical criteria may also be preferred [49],
to focus more on the consequences for decision making
[50]. Whatever criteria are used, we recommend they are
prespecified in a published protocol [51]. Visual plots of
calibration [23] and discrimination [52] are also important,
as neatly illustrated by Royston et al. [17]. Calibration es-
timates can also be obtained (and then meta-analyzed) for
particular subgroups within studies, for example, defined
by particular patient characteristics or categories of the
prognostic index [23]. Also, we note that excellent valida-
tion performance is not the end of the story: a prediction
model’s impact on patient outcomes also needs to be eval-
uated, for example, in subsequent trials [3].
A potential limitation of our work is the multivariate
normality assumption for the distribution of true perfor-
mance across studies. Although this is a common assump-
tion in the meta-analysis field, prediction intervals and
regions are potentially vulnerable to departures from this
[53]. A related issue is the choice of scale to use for the es-
timates of validation performance [16], and further research
is needed on this. Internaleexternal cross-validation is also
limited if the number of studies are small, and researchers
should ensure the number of events is suitable in each cycle
[54,55].
In conclusion, we propose multivariate meta-analysis for
external validation of the performance and implementation
of a prediction model when IPD are available for multiple
studies. The approach encourages researchers to focus not
only on average performance, but also on the consistencyin performance across populations, for both calibration
and discrimination.
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